The value of sotagliflozin in patients with diabetes and heart failure detracted by an unexpected ending.
Volpe M, Patrono C.
Eur Heart J · comment; journal article · DOI 10.1093/eurheartj/ehab136 PUBLICATION REGISTRY
Go to research.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för sotagliflozin. Visa hela publikationsregistret
A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publications in the selection
37 hitsCardiovascular Outcomes with Sotagliflozin.
Baglioni P.
N Engl J Med · letter; comment · DOI 10.1056/nejmc2102961Cardiovascular Outcomes with Sotagliflozin.
Marchand L, Villar E, Green L.
N Engl J Med · letter; comment · DOI 10.1056/nejmc2102961Cardiovascular Outcomes with Sotagliflozin. Reply.
Bhatt DL, Steg PG, Pitt B.
N Engl J Med · letter; comment · DOI 10.1056/nejmc2102961Sotagliflozin reduces adverse cardiovascular events.
Robson A.
Nat Rev Cardiol · comment; journal article · DOI 10.1038/s41569-020-00486-0An up-to-date evaluation of sotagliflozin for the treatment of type 1 diabetes.
Chatzopoulos G, Tziomalos K.
Expert Opin Pharmacother · review; journal article · DOI 10.1080/14656566.2020.1793961LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial.
Zambrowicz B, Freiman J, Brown PM, Frazier KS, Turnage A, Bronner J, Ruff D, Shadoan M, Banks P, Mseeh F, Rawlins DB, Goodwin NC, Mabon R, Harrison BA, Wilson A, Sands A, Powell DR.
Clin Pharmacol Ther · other; research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1038/clpt.2012.58